Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) and Echo Therapeutics (NASDAQ:ECTE) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, profitabiliy, institutional ownership, dividends and risk.
Institutional & Insider Ownership
17.5% of Tonix Pharmaceuticals Holding Corp. shares are owned by institutional investors. 4.0% of Tonix Pharmaceuticals Holding Corp. shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Volatility and Risk
Tonix Pharmaceuticals Holding Corp. has a beta of 2.84, suggesting that its share price is 184% more volatile than the S&P 500. Comparatively, Echo Therapeutics has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500.
Profitability
This table compares Tonix Pharmaceuticals Holding Corp. and Echo Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tonix Pharmaceuticals Holding Corp. | N/A | -107.33% | -97.16% |
| Echo Therapeutics | N/A | N/A | 216.11% |
Earnings and Valuation
This table compares Tonix Pharmaceuticals Holding Corp. and Echo Therapeutics’ gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | EBITDA | Earnings Per Share | Price/Earnings Ratio | |
| Tonix Pharmaceuticals Holding Corp. | N/A | N/A | -$29.87 million | ($11.25) | -0.39 |
| Echo Therapeutics | N/A | N/A | N/A | ($1.48) | -0.03 |
Tonix Pharmaceuticals Holding Corp. is trading at a lower price-to-earnings ratio than Echo Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of current recommendations and price targets for Tonix Pharmaceuticals Holding Corp. and Echo Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tonix Pharmaceuticals Holding Corp. | 0 | 3 | 1 | 0 | 2.25 |
| Echo Therapeutics | 0 | 0 | 0 | 0 | N/A |
Tonix Pharmaceuticals Holding Corp. presently has a consensus price target of $7.50, indicating a potential upside of 72.81%. Given Tonix Pharmaceuticals Holding Corp.’s higher probable upside, analysts clearly believe Tonix Pharmaceuticals Holding Corp. is more favorable than Echo Therapeutics.
Summary
Tonix Pharmaceuticals Holding Corp. beats Echo Therapeutics on 5 of the 8 factors compared between the two stocks.
About Echo Therapeutics
Echo Therapeutics, Inc. is a medical device company. The Company is engaged in developing a non-invasive, wireless continuous glucose monitoring (CGM) system with use in the wearable-health consumer market, diabetes outpatient market and in the hospital setting. The Company operates through the development of transdermal skin permeation and diagnostic medical devices segment. The Company has also developed its needle-free skin preparation device as a platform technology that allows for enhanced skin permeation enabling extraction of analytes, such as glucose, enhanced delivery of topical pharmaceuticals and other applications. The CGM System includes a skin preparation device, transdermal glucose sensor, battery and wireless transmitter. The Company has conducted several human feasibility clinical studies with its CGM System in healthy subjects, diabetics and critically ill patients, as well as a clinical study at several hospitals in the United States.
Receive News & Ratings for Tonix Pharmaceuticals Holding Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals Holding Corp. and related companies with MarketBeat.com's FREE daily email newsletter.
